| Abstrakt: |
A recent study conducted at the First Moscow State Medical University (Sechenov University) in Russia has explored the potential of gene therapy for the treatment of hemophilia. Hemophilia is a genetic disorder that results in insufficient levels of blood coagulation proteins, leading to bleeding episodes and complications. The current treatment involves lifelong replacement infusion therapy or monoclonal antibodies, which can be expensive and require constant administration. Gene therapy, on the other hand, offers a promising alternative by delivering a one-time vector to achieve long-term expression of the missing proteins. The study reviews the advancements in gene therapy for hemophilia and highlights its potential to overcome the limitations of traditional treatments. [Extracted from the article] |
